• metajournal
  • Join

    metajournal

    21 day free trial
    Articles. Pearls. Topics. Reviews. Journal Clubs.
    Stay informed.
  • Sign in
  • About
  • Pricing
  • Help
  • Blog
  • Articles
  • Knowledge
  • Topics
  • Notes



  • What are Calabadions? Can they replace sugammadex?

    Neuromuscular agents Sugammadex
     

    Calabadions are heterocyclics molecule that offers rapid and complete reversal of both aminosteroids, such as rocuronium and vecuronium, and benzylisoquinoline NMBDS, such as atracurium and cisatracurium.

    Notably, calabadion 2 binds rocuronium 89 times stronger than sugammadex. Additionally it also binds etomidate and ketamine.

    Calabadions are still undergoing pre-human animal testing, and so are some time away from entering clinical practice.

    summary

    • Article

      Calabadion: A New Agent to Reverse the Effects of Benzylisoquinoline and Steroidal Neuromuscular-blocking Agents.

      Anesthesiology. 2013 Aug 1; 119 (2): 317-25.

    • Comparative Study

      Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.

      Anesthesiology. 2015 Dec 1;123(6):1337-49.

    • Article

      A Novel Strategy to Reverse General Anesthesia by Scavenging with the Acyclic Cucurbit[n]uril-type Molecular Container Calabadion 2.

      Anesthesiology. 2016 Aug 1; 125 (2): 333-45.

    expand and show 2 more articles

       

    Daniel Jolley.

    5 articles.

    Created July 16, 2019, last updated about 5 years ago.

    Private Empty Deleted


    Collection: 98, Score: 3258, Trend score: 0, Read count: 3257, Articles count: 5, Created: 2019-07-16 09:00:43 UTC. Updated: 2021-02-08 23:55:48 UTC.

    Notes

    summary
    1

    Calabadions are heterocyclics molecule that offers rapid and complete reversal of both aminosteroids, such as rocuronium and vecuronium, and benzylisoquinoline NMBDS, such as atracurium and cisatracurium.

    Notably, calabadion 2 binds rocuronium 89 times stronger than sugammadex. Additionally it also binds etomidate and ketamine.

    Calabadions are still undergoing pre-human animal testing, and so are some time away from entering clinical practice.

    Daniel Jolley  Daniel Jolley
     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    Collected Articles

    • Anesthesiology · Aug 2013

      Calabadion: A New Agent to Reverse the Effects of Benzylisoquinoline and Steroidal Neuromuscular-blocking Agents.

      Calabadion is a new heterocyclic molecule that offers rapid and complete reversal of both aminosteroids, such as rocuronium, and benzylisoquinoline NMBDS, such as cisatracurium.

      summary

      expand abstract… mark as read…

    • Anesthesiology · Dec 2015

      Comparative Study

      Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.

      The authors evaluated the comparative effectiveness of calabadion 2 to reverse non-depolarizing neuromuscular-blocking agents (NMBAs) by binding and inactivation. ⋯ Calabadion 2 reverses NMB induced by benzylisoquinolines and steroidal NMBAs in rats more effectively, i.e., faster than sugammadex. Calabadion 2 is eliminated in the urine and well tolerated in rats.

      keep going… or not…

    • Anesthesiology · Aug 2016

      A Novel Strategy to Reverse General Anesthesia by Scavenging with the Acyclic Cucurbit[n]uril-type Molecular Container Calabadion 2.

      Calabadion 2 is a new drug-encapsulating agent. In this study, the authors aim to assess its utility as an agent to reverse general anesthesia with etomidate and ketamine and facilitate recovery. ⋯ Calabadion 2 reverses etomidate and ketamine anesthesia in rats by chemical encapsulation at nontoxic concentrations.

      expand abstract… or not…

    • Anesthesiology · Jun 2016

      Comment Letter

      Effectiveness versus Efficacy of Calabadion and Sugammadex for Nondepolarizing Neuromuscular Blocking Agent Reversal.

      no abstract available

      read more… or not…

    • Curr Anesthesiol Rep · Jan 2018

      Review

      New Drug Developments for Neuromuscular Blockade and Reversal: Gantacurium, CW002, CW011, and Calabadion.

      The purpose of this chapter is to provide a brief review of the literature on the recent developments in neuromuscular blockade and reversal agents. ⋯ Recent advancements in neuromuscular blocking agents and reversal drugs have shown promise in improving safety of management of neuromuscular blockade. Preclinical and clinical studies are discussed. However, to date these new drugs are not yet available for clinical use.

      keep reading… or not…

    Add articles to this collection...

    collapse collection…


Loading...

Welcome to metajournal!

Sign up for your free metajournal

Receive a weekly email with the highest quality and most significant abstracts from critical care specialties.

Anesthesiology, Critical Care Medicine, Emergency Medicine, Medicine, and Pain medicine.

Includes a free 21 day trial of metajournal premium

  • Personalized abstracts
  • Institutional full-text access
  • Article collections
  • Save favorite articles
  • CME audit reports
  • Journal clubs and more...

We guarantee your privacy. Your email address will not be shared. Unsubscribe anytime.

No thanks, I'm up to date...
metajournal.com @themetajournal by @djoll · Privacy Policy · Terms of Service · v2.0.1
  • About
  • ·
  • Contact
  • ·
  • Pricing
  • ·
  • Help
  • ·
  • FAQ
  • ·
  • Blog
Copyright © 2026 Metajournal Pty Ltd. ACN 600 504 363. ABN 47 600 504 363. Hobart TAS, AUSTRALIA.
Publication data is provided by the National Library of Medicine and PubMed. Please refer to the NCBI's Disclaimer and Copyright notice.